XML 72 R62.htm IDEA: XBRL DOCUMENT v3.23.1
EQUITY-BASED INCENTIVE PLANS - Nonvested Restricted Stock Activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
3 Months Ended 12 Months Ended
Mar. 31, 2023
Dec. 31, 2021
RSAs    
Shares    
Number of nonvested shares outstanding, beginning 406,001  
Nonvested shares granted 0  
Nonvested shares vested (131,001)  
Nonvested shares forfeited (17,500)  
Number of nonvested shares outstanding, ending 257,500  
Unrecognized stock-based compensation expense $ 861  
Weighted Average Grant Date Fair Value    
Weighted average exercise price outstanding, beginning (in usd per share) $ 4.02  
Weighted average exercise price outstanding, nonvested options granted (in usd per share) 0  
Weighted average exercise price outstanding, options vested (in usd per share) 4.18  
Weighted average exercise price outstanding, options forfeited (in usd per share) 5.14  
Weighted average exercise price outstanding, ending (in usd per share) $ 3.85  
Weighted average remaining vesting period 1 year 7 months 6 days  
RSUs    
Shares    
Number of nonvested shares outstanding, beginning 450,000  
Nonvested shares vested (241,542)  
Nonvested shares forfeited   (450,000)
Number of nonvested shares outstanding, ending 94,863  
Unrecognized stock-based compensation expense $ 3,863  
Restricted Shares    
Nonvested restricted stock outstanding, beginning balance (in shares) 842,302  
Nonvested restricted stock granted (in shares) 509,798  
Nonvested restricted stock vested (in shares) (110,541)  
Nonvested restricted stock forfeited (in shares) (126,666)  
Nonvested restricted stock outstanding, ending balance (in shares) 1,114,893  
Weighted Average Grant Date Fair Value    
Weighted average exercise price outstanding, beginning (in usd per share) $ 4.42  
Weighted average exercise price outstanding, nonvested options granted (in usd per share) 4.27  
Weighted average exercise price outstanding, options vested (in usd per share) 3.90  
Weighted average exercise price outstanding, options forfeited (in usd per share) 4.59  
Weighted average exercise price outstanding, ending (in usd per share) $ 4.39  
Weighted average remaining vesting period 2 years 4 months 24 days